Shanghai, China
Shanghai, China

Tongji University , colloquially known as Tongji , located in Shanghai, has more than 50,000 students and 8,000 staff members . It offers degree programs at both undergraduate and postgraduate levels. Established in 1907 by the German government together with German physicians in Shanghai, Tongji is one of the oldest and most prestigious universities in China. Among its various departments it is especially highly ranked in engineering, among which its architecture, urban planning and civil engineering departments have consistently ranked first in China for decades, and its automotive engineering, oceanography, environmental science, software engineering, German language departments are also ones of the best domestically. Wikipedia.


Time filter

Source Type

Patent
Tongji University | Date: 2016-11-29

To provide a modified forward osmosis (FO) membrane module for flow regime improvement, the FO membrane module includes but not limited to: a water inlet; a water outlet; a forward osmosis (FO) membrane; a frame; and folded plates for improving flow regime in which draw solution is introduced into the water inlet of membrane module, then flowed through flow channels composed by three opposite folded plates vertically arranged on upper and bottom portions of the frame alternatively along horizontal direction with equal space; and drawn out from the water outlet. The flow regime improvement is achieved by increasing number of flow-guide folded plate, which results in the decrease of internal concentration polarization and membrane fouling. Structure of frame is modified to improve flow regime and to satisfy requirement of convenient and reliable connections between numbers of membrane modules in the FO membrane system.


This present disclosure relates to a highly effective sewage treatment based on regulation and control of directed electron flow and apparatus thereof The apparatus includes an anaerobic fermentation electron generation chamber, a heterotrophic-autotrophic denitrification chamber and an aerobic membrane separation chamber. Low concentrated organic sewage is introduced into anaerobic fermentation electron generation chamber; then, particulate and partly dissolved organic substances are intercepted and absorbed by carrier materials; and extracellular currents generated by microorganism reaction are used in following autotrophic denitrification processing. Micro-/ultra-membrane separation processing is used to improve operation load and solid-liquid separation effect of sewage treatment and thereby effluent could meet the high recycling standards. The directed electron flow is regulated and controlled to enhance nutrients removal and to reduce sludge yield and fouling rate of membrane. The sewage treatment could efficiently treat low concentrated organic sewage at normal temperature (>15 C.) and dramatically decrease energy consumption.


The present invention relates to pharmaceutical and medical technologies, and more particularly to novel nanobodies against pulmonary surfactant protein A (SP-A) and their preparation methods. The nanobodies of the present invention comprises an amino acid sequence having certain formula. The present invention also relates to nucleic acid sequences encoding the nanobodies, their preparation method and their applications. Immunohistochemistry and in vivo imaging show that the nanobodies of the present inventions have high lung-targeting specificity.


Patent
Tongji University and ZTE Corporation | Date: 2015-02-16

Provided are methods and devices for coding or decoding an image. The coding method includes that: one coding manner is selected for predictive or matching coding of a current CU, according to characteristics of pixel samples of the current CU and an adjacent CU of the current CU, from A predetermined predictive coding manners and matching coding manners including at least one predictive coding manner with different prediction characteristics and matching coding manners with mutually different matching characteristics, and the selected coding manner is determined as an optimal coding manner, wherein the A predictive coding manners and matching coding manners include: a predictive coding manner, matching coding manner 1, matching coding manner 2, . . . and matching coding manner A-1, and A is an integer more than or equal to 2; and predictive coding or matching coding is performed on the current CU by adopting the optimal coding manner.


This invention provides a polymeric separation membrane that has excellent durable antibacterial effect and stain resistance, and a preparation method thereof. The polymeric separation membrane can be widely applied for water treatment, which belongs to the field of water treatment and membrane separation science and technology. The polymeric separation membrane containing quaternary ammonium salt is prepared by the immersion precipitation phase inversion method, using quaternary ammonium salt mixed with polymer and additives. This modification method effectively improves the antibacterial and antifouling ability of the polymeric separation membrane prolongs the service life of membranes and significantly inhibits the reproduction of bacterial and microbial. The preparation method has the advantages of simple process, easy operation, easy for promotion, and also avoids expensive equipment. The polymeric separation membrane has great antibacterial ability and stain resistance, therefore, it has potential application in the field of water treatment.


The present invention relates to a method for inhibiting the formation of dioxin-like compounds in solid waste incineration flue gases, belonging to the field of cleaning of solid waste incineration flue gases. In accordance with the present invention, when incineration flue gases cool down to 500450 C., the flue gases are introduced into an inhibition reactor where copper chlorides in flue gas particulates mix and react with inhibitors to convert into copper metaphosphate so as to inactivate the copper chlorides which can catalyze the formation of dioxin-like compounds and control dioxin-like compound pollutants in incineration flue gases at the source. Compared with the prior art, the invention can effectively control the main formation ways of dioxin-like compounds in solid waste incineration flue gases by optimizing inhibitors and reaction conditions. The method of the invention does not affect the residual heat utilization of solid waste incineration flue gases, so solid waste incineration has a better resource utilization effect. The ammonium dihydrogen phosphate inhibitor used in the invention has the advantages of high inhibition efficiency, strong operability, low cost and environment protection, providing the technology with good application feasibility.


SHANGHAI, China and CUPERTINO, Calif., May 15, 2017 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in the development of effective immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced the addition of a new independent Phase I clinical trial of the Company’s ongoing CARD-1 study in patients with chemorefractory and aggressive DLBCL. The Company and Shanghai Tongji Hospital (Tongji) are conducting a single arm, non-randomized study to evaluate the safety and efficacy of C-CAR011 (Anti-CD19 single-chain variable fragment (scFv) (41BB-CD3ζ)) therapy in relapsed or refractory B cell Non-Hodgkin Lymphoma (NHL). The trial will enroll 15 patients comprised of DLBCL, Primary Mediastinal Large B-Cell Lymphoma (PMBCL) and Follicular Lymphoma (FL). “Driven by Shanghai’s regional demand, Tongji’s CAR-T expertise, the requirement to confirm site to site consistency and our need to prepare for the next phase of a confirmatory clinical trial, the new trial will benefit patients in Shanghai and provide CBMG with incremental data in safety and tolerability of C-CAR011 in more chemorefractory and aggressive DLBCL patients comprised of unique histogenesis and those with the most common indolent form of non-Hodgkin lymphoma (NHL),” said Mr. Tony Liu, Chief Executive Officer for CBMG. Mr. Tony Liu added, “Due to our robust clinical pipeline, we believe the Company’s stock is currently undervalued. The management and our scientific team are committed to delivering long-term clinical benefits to patients that have the potential to address very large cancer and knee osteoarthritis markets and create long-term value for shareholders. We believe that CBMG has one of the very few leading integrated chemistry, manufacturing, and controls (CMC) facilities in the world for a cell therapy company, which when fully built out in China, will have the manufacturing capacity to support the treatment of 10,000 cancer and 10,000 knee osteoarthritis patients per year.  With a healthy balance sheet and an efficient deployment of capital that will enable CBMG to execute on its clinical developments over the next twelve months, we are well equipped to further our clinical trials including the addition of new cancer indications by adding more top cancer centers in China for DLBCL and ALL trials using our C-CAR011 product. As a reminder, each year China has approximately five million new cancer patients, which far surpasses the U.S.  We are pleased with our CAR-T patient screening and trial enrollment progress thus far and are on track to share our topline clinical data in the fourth quarter of this year as it becomes available.  We look forward to evaluating new interests in expanding our clinical development and CAR-T partnerships with leading hospitals in major cities in China.” About Cellular Biomedicine Group Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) develops proprietary cell therapies for the treatment of cancer and degenerative diseases. We conduct immuno-oncology and stem cell clinical trials in China using products from our integrated GMP laboratory. Our GMP facilities in China, consisting of twelve independent cell production lines, are designed and managed according to both China and U.S. GMP standards.  CBMG recently commenced two Phase I human clinical trials in China using CAR-T to treat relapsed/refractory CD19+ B-cell Acute Lymphoblastic Leukemia (ALL) and Refractory Diffuse Large B-cell Lymphoma (DLBCL) as well as an ongoing Phase I trial in China for AlloJoinTM (CBMG’s “Off-the-Shelf” Allogeneic Human Adipose-derived Mesenchymal Stem Cell) for the treatment of Knee Osteoarthritis (KOA). CBMG was recently awarded $2.29 million from the California Institute for Regenerative Medicine (CIRM) to support pre-clinical studies of AlloJoinTM for Knee Osteoarthritis in the United States. The Company also recently announced a strategic partnership with GE Healthcare Life Sciences China to establish a joint technology laboratory to develop control processes for the manufacture of CAR-T and stem cell therapies. To learn more about CBMG, please visit www.cellbiomedgroup.com. About Shanghai Tongji Hospital Established in 1900, Shanghai Tongji Hospital, a AAA General Hospital in Shanghai, China, is affiliated with Tongji University, one of the oldest and most prestigious universities in China. The hospital comprises 52 clinical and paramedical departments with a total of 4,000 beds and over 4,500 employees. The Department of Rehabilitation is designated as a training and research center of World Health Organization (WHO). The hospital maintains cooperative relationships with other research hospitals and laboratories in many countries including Germany, USA, Japan and France. It has published more research papers than any other medical institution in China. About PMBCL & FL Primary mediastinal B-cell lymphoma (PMBCL) belongs to the group of aggressive diffuse large B-cell lymphomas. Its molecular signature and clinical features resemble classical Hodgkin lymphoma. It constitutes approximately 2 % to 4 % of all non-Hodgkin lymphomas (around 6 % of diffuse large B-cell lymphomas (DLBCL)).  Follicular lymphoma (FL) is the most common indolent (slow- growing) form of NHL, accounting for approximately 12 percent of all B-cell NHLs. Forward-Looking Statements Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include risks inherent in doing business, trends affecting the global economy, including the devaluation of the RMB by China in August 2015 and other risks detailed from time to time in CBMG’s reports filed with the Securities and Exchange Commission, quarterly reports on form 10-Q, current reports on form 8-K and annual reports on form 10-K. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.


A method for measuring user behavior consistency degree based on a complex correspondence system, which is applied to internet payment platform security. An entire solution is divided into three stages: at a first stage, analyzing complex correspondence relation characteristics according to an existing user behavior model; at a second stage, establishing a behavior profile according to user behavior characteristics and establishing user behavior relation matrixes; and at a third stage, completing user behavior matrix decomposition according to the complex correspondence characteristics of a user, calculating a user behavior consistency degree and detecting a degree of consistency between user behaviors and expected behaviors. The internal behavior relation of the user is more elaborately analyzed, the user behavior relation profile is established, the complex correspondence relations are distinguished and classified, and user behavior consistency measurement and analysis architecture based on the complex correspondence relations are given.


Patent
Tongji University and ZTE Corporation | Date: 2017-06-07

An image coding method and apparatus and an image decoding method and apparatus are provided by the present invention. The image coding method includes: implementing matching coding for pixels of an input video image to obtain one or more matching relationship parameters, herein the matching relationship parameters are parameters used in a process of constructing predicted values and/or reconstructed values of the pixels in the image; mapping the matching relationship parameters to obtain mapped values of the matching relationship parameters; and performing entropy coding on the mapped values of the matching relationship parameters. The present invention addresses the problem existing in the conventional art which is caused by the direct implementation of entropy coding for matching relationship parameters and achieves a good data compression effect through entropy coding.


Patent
Tongji University | Date: 2014-09-05

The present invention is to code a current pattern using a reference pattern that has different shape and/or size from the current pattern being coded. A portion or entire of the reference pattern provides reference pixels for one part of the current pattern. A portion or entire of the reference pattern also provides or repeatedly reference pixels for the other part of the current pattern.

Loading Tongji University collaborators
Loading Tongji University collaborators